Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia

Journal of Biological Chemistry

Volumn 289, Issue 22, 2014, Pages 15642-15652

  Waight, Jeremy D ^a   Banik, Debarati ^a   Griffiths, Elizabeth A ^a   Nemeth, Michael J ^a   Abrams, Scott I ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION; TRANSCRIPTION FACTORS;

CHRONIC MYELOID LEUKEMIAS; SIGNAL TRANSDUCERS; TUMOR SUPPRESSOR GENES;

DISEASES;

BCR ABL PROTEIN; IMATINIB; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; STAT5 PROTEIN;

ADULT; AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTERFERON REGULATORY FACTOR 8 GENE; LEUKEMIA CELL; MALE; MIDDLE AGED; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

CANCER THERAPY; CELL DEATH; LEUKEMIA; STAT TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZAMIDES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON REGULATORY FACTORS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROMOTER REGIONS, GENETIC; PYRIMIDINES; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84901711194     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.544320     Document Type: Article

References (46)

1. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037
2. Shtivelman, E., Lifshitz, B., Gale, R. P., and Canaani, E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550-554
3. Daley, G. Q., Van Etten, R. A., and Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830
4. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R. A., and IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417
5. Ilaria, R. L., Jr., and Van Etten, R. A. (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation andDNAbinding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704-31710
6. Carlesso, N., Frank, D. A., and Griffin, J. D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183, 811-820
7. Warsch, W., Kollmann, K., Eckelhart, E., Fajmann, S., Cerny-Reiterer, S., Hölbl, A., Gleixner, K. V., Dworzak, M., Mayerhofer, M., Hoermann, G., Herrmann, H., Sillaber, C., Egger, G., Valent, P., Moriggl, R., and Sexl, V. (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117, 3409-3420
8. Ihle, J. N., and Kerr, I. M. (1995) Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11, 69-74
9. Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., and Sawyers, C. L. (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254
10. Moriggl, R., Topham, D. J., Teglund, S., Sexl, V., McKay, C., Wang, D., Hoffmeyer, A., van Deursen, J., Sangster, M. Y., Bunting, K. D., Grosveld, G. C., and Ihle, J. N. (1999) Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10, 249-259
11. Moriggl, R., Sexl, V., Piekorz, R., Topham, D., and Ihle, J. N. (1999) Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity 11, 225-230
12. Lord, J. D., McIntosh, B. C., Greenberg, P. D., and Nelson, B. H. (2000) The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164, 2533-2541
13. Ye, D., Wolff, N., Li, L., Zhang, S., and Ilaria, R. L. (2006) STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107, 4917-4925
14. Hoelbl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoelzl, M. A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., Hennighausen, L., Poli, V., Beug, H., Moriggl, R., and Sexl, V. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2, 98-110
15. Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M., Waring, J. F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I., and Neubauer, A. (1998) Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91, 22-29
16. Tamura, T., Yanai, H., Savitsky, D., and Taniguchi, T. (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev. Immunol. 26, 535-584
17. Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K. P., Gabriele, L., Waring, J. F., Bachmann, M. F., Zinkernagel, R. M., Morse, H. C., 3rd, Ozato, K., and Horak, I. (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307-317
18. Konieczna, I., Horvath, E., Wang, H., Lindsey, S., Saberwal, G., Bei, L., Huang, W., Platanias, L., and Eklund, E. A. (2008) Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J. Clin. Invest. 118, 853-867
19. Koenigsmann, J., Rudolph, C., Sander, S., Kershaw, O., Gruber, A. D., Bullinger, L., Schlegelberger, B., and Carstanjen, D. (2009) Nf1 haploinsufficiency and Icsbp deficiency synergize in the development of leukemias. Blood 113, 4690-4701
20. Hao, S. X., and Ren, R. (2000) Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol. Cell. Biol. 20, 1149-1161
21. Burchert, A., Cai, D., Hofbauer, L. C., Samuelsson, M. K., Slater, E. P., Duyster, J., Ritter, M., Hochhaus, A., Müller, R., Eilers, M., Schmidt, M., and Neubauer, A. (2004) Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 103, 3480-3489
22. Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R., and Neubauer, A. (2001) Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood 97, 3648-3650
23. Esashi, E., Wang, Y. H., Perng, O., Qin, X. F., Liu, Y. J., and Watowich, S. S. (2008) The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28, 509-520
24. Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., and Abrams, S. I. (2013) Myeloid-derived suppressor cell development is regulated by a STAT/ IRF-8 axis. J. Clin. Invest. 123, 4464-4478
25. Banik, D., Khan, A. N., Walseng, E., Segal, B. H., and Abrams, S. I. (2012) Interferon regulatory factor-8 is important for histone deacetylase inhibitor- mediated antitumor activity. PLoS One 7, e45422
26. Kanno, Y., Kozak, C. A., Schindler, C., Driggers, P. H., Ennist, D. L., Gleason, S. L., Darnell, J. E., Jr., and Ozato, K. (1993) The genomic structure of the murine ICSBP gene reveals the presence of the γ interferon-responsive element, to which an ISGF3α subunit (or similar) molecule binds. Mol. Cell. Biol. 13, 3951-3963
27. Li, G., Miskimen, K. L., Wang, Z., Xie, X. Y., Tse, W., Gouilleux, F., Moriggl, R., and Bunting, K. D. (2010) Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 24, 1397-1405
28. Oda, T., Heaney, C., Hagopian, J. R., Okuda, K., Griffin, J. D., and Druker, B. J. (1994) Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925-22928
29. ten Hoeve, J., Arlinghaus, R. B., Guo, J. Q., Heisterkamp, N., and Groffen, J. (1994) Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood 84, 1731-1736
30. Seo, J. H., Wood, L. J., Agarwal, A., O'Hare, T., Elsea, C. R., Griswold, I. J., Deininger, M. W., Imamoto, A., and Druker, B. J. (2010)Aspecific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res. 70, 7325-7335
31. Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., and Bromberg, J. F. (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U.S.A. 101, 10602-10607
32. Coppo, P., Flamant, S., De Mas, V., Jarrier, P., Guillier, M., Bonnet, M. L., Lacout, C., Guilhot, F., Vainchenker, W., and Turhan, A. G. (2006) BCRABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol. 134, 171-179
33. Yang, D., Thangaraju, M., Greeneltch, K., Browning, D. D., Schoenlein, P. V., Tamura, T., Ozato, K., Ganapathy, V., Abrams, S. I., and Liu, K. (2007) Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 67, 3301-3309
34. Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., Ebert, B. L., Griffin, J. D., and Frank, D. A. (2011) The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117, 3421-3429
35. Burchert, A., Wang, Y., Cai, D., von Bubnoff, N., Paschka, P., Müller- Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., and Neubauer, A. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19, 1774-1782
36. Tamura, T., Kong, H. J., Tunyaplin, C., Tsujimura, H., Calame, K., and Ozato, K. (2003) ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood 102, 4547-4554
37. Schmidt, M., Bies, J., Tamura, T., Ozato, K., and Wolff, L. (2004) The interferon regulatory factor ICSBP/IRF-8 in combination with PU. 1 upregulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood 103, 4142-4149
38. Hu, X., Yang, D., Zimmerman, M., Liu, F., Yang, J., Kannan, S., Burchert, A., Szulc, Z., Bielawska, A., Ozato, K., Bhalla, K., and Liu, K. (2011) IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 71, 2882-2891
39. Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A., and Reya, T. (2007) Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-541
40. Huang, W., Zhou, W., Saberwal, G., Konieczna, I., Horvath, E., Katsoulidis, E., Platanias, L. C., and Eklund, E. A. (2010) Interferon consensus sequence binding protein (ICSBP) decreases β-catenin activity in myeloid cells by repressing GAS2 transcription. Mol. Cell. Biol. 30, 4575-4594
41. Vidovic, K., Svensson, E., Nilsson, B., Thuresson, B., Olofsson, T., Lennartsson, A., and Gullberg, U. (2010) Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia 24, 992-1000
42. Rong, Y., Cheng, L., Ning, H., Zou, J., Zhang, Y., Xu, F., Liu, L., Chang, Z., and Fu, X. Y. (2006) Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res. 66, 8049-8057
43. Zhou, J., Bi, C., Janakakumara, J. V., Liu, S. C., Chng, W. J., Tay, K. G., Poon, L. F., Xie, Z., Palaniyandi, S., Yu, H., Glaser, K. B., Albert, D. H., Davidsen, S. K., and Chen, C. S. (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113, 4052-4062
44. Weber-Nordt, R. M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88, 809-816
45. Heltemes-Harris, L. M., Willette, M. J.., Ramsey, L. B., Qiu, Y. H., Neeley, E. S., Zhang, N., Thomas, D. A., Koeuth, T., Baechler, E. C., Kornblau, S. M., and Farrar, M. A. (2011) Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J. Exp. Med. 208, 1135-1149
46. Qian, Z., Fernald, A. A., Godley, L. A., Larson, R. A., and Le Beau, M. M. (2002) Expression profiling of CD34 + hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 14925-14930